# A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

> **NCT02966782** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 70 (actual)

## Conditions studied

- Myelodysplastic Syndromes (MDS)

## Interventions

- **DRUG:** venetoclax
- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT02966782
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-07
- **Primary completion:** 2023-04-05
- **Final completion:** 2023-04-05
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02966782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02966782, "A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT02966782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*